Maladies peptiques [Acid related diseases progress in 2007].

Détails

ID Serval
serval:BIB_413B6D610D71
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Maladies peptiques [Acid related diseases progress in 2007].
Périodique
Revue Médicale Suisse
Auteur⸱e⸱s
Vouillamoz D., Jornod P., Viani F., Nichita C., Dorta G.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2008
Volume
4
Numéro
141
Pages
190-194
Langue
français
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Résumé
The treatment of reflux disease did not changed. PPI treatment remains the first line treatment and surgery a second line treatment. The effect of surgery in reflux disease reduces and, after ten years, a part of the operated patients needs PPI again. The triple therapy is the treatment of choice of Helicobacter pylori infection. Patients with persistent Helicobacter pylori infection, after a first treatment, should be treated with a sequential treatment. PPI are effective in the prevention of gastroduodenal lesions and in the treatment of dyspeptic symptoms during NSAID treatment. IPP should be given to all patients presenting dyspeptic symptoms under NSAID or COX-2 administration.
Mots-clé
Esophagitis, Peptic/drug therapy, Esophagitis, Peptic/therapy, Gastroesophageal Reflux/drug therapy, Gastroesophageal Reflux/therapy, Helicobacter Infections/drug therapy, Helicobacter pylori, Humans, Stomach Diseases/drug therapy, Stomach Diseases/microbiology
Pubmed
Création de la notice
02/03/2009 13:47
Dernière modification de la notice
20/08/2019 13:41
Données d'usage